Therefore, the present study preliminarily offers evidence for the feasibility of using combined detection of FAS and mHER2 in GC patients, which appears most significant in mHER2-negative patients and mHER2-positive patients who are resistant to HER2-targeted therapy. This evidence concerns the gene ERBB2 and gastric cancer.